iRhythm Technologies and Movano, two medical companies, are facing investment scrutiny regarding their services providing ambulatory cardiac monitoring in the US.
2 reports, 2 independent
Updated May 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
iRhythm Technologies and Movano, two medical companies, are facing investment scrutiny regarding their services providing ambulatory cardiac monitoring in the US.
How it developed
Newest first. Tap a step to see who reported it.- An Avalon study found that Zio led to faster diagnoses and lower costs.Sub-event
Two medical companies, iRhythm and Movano, are under investment scrutiny for their ambulatory cardiac monitoring services in the US.1 source
Coverage
Newest first; wire copies grouped- dailypolitical.com
- ZacksIRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection iRhythm Technologies, Inc. IRTC recently published the results from the Oxford University-led Active Monitoring for AtriaL FIbrilla